APA (7th ed.) Citation

Chen, R., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., . . . Younes, A. (2016). Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood, 128(12), 1562. https://doi.org/10.1182/blood-2016-02-699850

Chicago Style (17th ed.) Citation

Chen, Robert, et al. "Five-year Survival and Durability Results of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma." Blood 128, no. 12 (2016): 1562. https://doi.org/10.1182/blood-2016-02-699850.

MLA (9th ed.) Citation

Chen, Robert, et al. "Five-year Survival and Durability Results of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma." Blood, vol. 128, no. 12, 2016, p. 1562, https://doi.org/10.1182/blood-2016-02-699850.